Episode 106: Potential Role of Stathmin-2 in Amyotrophic Lateral Sclerosis
Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Cathleen Lutz, PhD. [LISTEN TIME: 18 minutes]
Episode 106 of the NeurologyLive®
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 106, "Recapping Conversations in Neurology From 2023" features a conversation with Cathleen Lutz, PhD, vice president of the Rare Disease Translational Center at the Jackson Laboratory, who provided comment on a recently published study on the role of stathmin-2 loss leads to in patients with amyotrophic lateral sclerosis (ALS). Lutz offered insight on the role stathmin-2 may have in this disease, the questions that still remain, and whether restoration of stathmin-2 may be an attractive therapeutic approach. Furthermore, she spoke on the potential of this protein as a disease-modifying biomarker and whether it may be incorporated in trials in the near future.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
FDA Clears Phase 2 KYSA-7 Study of CAR T-Cell Therapy in Refractory Progressive Multiple Sclerosis Dyne Reports Positive Phase 1/2 Data for Duchenne Agent DYNE-251 Parkinson Gene Therapy AB-1005 Meets Primary End Point in Phase 1b Trial VISIONARY-MS Trial Reports CNM-Au8 Improves Vision and Cognition in Multiple Sclerosis
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at
EPISODE BREAKDOWN
- 1:15 – Idea behind studying stathmin-2
- 2:45 – Overviewing study results
- 7:05 – Next steps in extending this research
- 8:40 – Neurology News Minute
- 11:30 – Stathmin-2's connection with neurofilament light
- 12:55 – Potential of stathmin-2 as ALS-specific biomarker
- 14:45 – Future use of stathmin-2 in clinical trials
- 15:30 – Closing thoughts
Hoping to listen on your favorite podcast app? See below:
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
